New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4589120)

Published in Transl Neurodegener on September 30, 2015

Authors

Xueping Chen1, Hui-Fang Shang1

Author Affiliations

1: Department of Neurology, West China Hospital, Sichuan University, 610041 Chengdu, Sichuan China.

Articles cited by this

(truncated to the top 100)

Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42

Electrical impedance myography: Background, current state, and future directions. Muscle Nerve (2009) 3.36

Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol (2014) 2.99

Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry (1990) 2.91

Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology (2009) 2.60

Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry (2011) 2.48

Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol (2004) 2.46

Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol (2007) 2.37

The natural history of primary lateral sclerosis. Neurology (2006) 2.31

Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis (2004) 2.29

Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem (2005) 1.91

Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology (2011) 1.87

CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology (2010) 1.77

Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology (2010) 1.69

Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain (2014) 1.67

Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol (2001) 1.67

Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci (2004) 1.65

Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. Neurology (2012) 1.64

Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology (2007) 1.63

Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler (2012) 1.62

Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59

Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain (2011) 1.57

Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry (2015) 1.52

Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol (2015) 1.52

Muscle ultrasonography: a diagnostic tool for amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52

Identification of potential CSF biomarkers in ALS. Neurology (2006) 1.50

Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology (2011) 1.49

Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49

Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47

The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci (2010) 1.45

Muscle ultrasonography as an additional diagnostic tool for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2014) 1.44

Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. Neurol Sci (2010) 1.44

Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain (2006) 1.33

Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry (2003) 1.33

Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain (1993) 1.31

Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol (2008) 1.30

Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study. PLoS One (2010) 1.30

Neuroimaging in amyotrophic lateral sclerosis. Biomark Med (2012) 1.23

Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp (2011) 1.23

Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology (2015) 1.21

Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.18

S100B protein in neurodegenerative disorders. Clin Chem Lab Med (2011) 1.14

Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better? Amyotroph Lateral Scler (2010) 1.13

Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol (2005) 1.11

A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve (1997) 1.11

Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem (2011) 1.10

Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol (2012) 1.09

Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 1.06

Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci (2009) 1.05

A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry (2008) 1.05

Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology (2009) 1.04

Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol (2012) 1.04

Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve (2013) 1.03

Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler (2010) 1.03

Progression of cortical and spinal dysfunctions over time in amyotrophic lateral sclerosis. Muscle Nerve (2008) 1.02

The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis. Amyotroph Lateral Scler (2010) 1.01

Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2006) 1.00

Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process? Proteomics (2005) 0.99

Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotroph Lateral Scler Frontotemporal Degener (2012) 0.99

Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve (2007) 0.98

Motor unit number estimation. Phys Med Rehabil Clin N Am (2003) 0.98

Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.96

Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: A tensor based morphometry study. Amyotroph Lateral Scler (2009) 0.96

Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci Lett (2009) 0.94

Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler (2011) 0.94

25 years of neuroimaging in amyotrophic lateral sclerosis. Nat Rev Neurol (2013) 0.93

Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res (2005) 0.92

Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol (2009) 0.92

Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2012) 0.91

1H MRS of basal ganglia and thalamus in amyotrophic lateral sclerosis. NMR Biomed (2011) 0.91

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.90

Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol (2014) 0.90

Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler (2010) 0.90

Correlation between structural and functional connectivity impairment in amyotrophic lateral sclerosis. Hum Brain Mapp (2014) 0.90

A meta-analysis of diffusion tensor imaging studies in amyotrophic lateral sclerosis. Neurobiol Aging (2011) 0.90

CSF markers in amyotrophic lateral sclerosis. J Neural Transm (Vienna) (2012) 0.90

Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis. Muscle Nerve (2015) 0.89

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol (2014) 0.89

Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology (2011) 0.89

[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain (2005) 0.88

Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol (2014) 0.88

Cystatin C, a cysteine protease inhibitor, is persistently up-regulated in neurons and glia in a rat model for mesial temporal lobe epilepsy. Eur J Neurosci (2001) 0.87

Modulation of chitotriosidase during macrophage differentiation. Cell Biochem Biophys (2013) 0.86

Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci (2014) 0.86

Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.85

Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology (Berl) (2007) 0.85

The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria. Behav Neurol (2013) 0.84

Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease. Acta Myol (2006) 0.83

Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci Lett (2006) 0.83

Plasma chitotriosidase in health and pathology. Clin Lab (2007) 0.82

Degeneration of the mid-cingulate cortex in amyotrophic lateral sclerosis detected in vivo with MR spectroscopy. AJNR Am J Neuroradiol (2010) 0.81

Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics (2013) 0.81

Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol (2007) 0.81

Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neural Transm (Vienna) (2009) 0.81

CSF markers in amyotrophic lateral sclerosis: has the time come? Neurology (2010) 0.80

Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res (2007) 0.80

Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 0.80

Smads as muscle biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol (2014) 0.78